Terms: = Bone cancer AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7 AND Treatment
378 results:
1. [Clinical Characteristics of CD4
He HS; Wei YF; Ji XY; Xu YH; Yang YQ; Jin XK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):588-594. PubMed ID: 38660871
[TBL] [Abstract] [Full Text] [Related]
2. Mycosis fungoides with large cell transformation (CD30+) and B-cell chronic lymphocytic leukemia.
Petković M; Ilić I; Jurakić Tončić R; Radman-Livaja I; Čeović R
Acta Dermatovenerol Croat; 2023 Dec; 31(4):223-224. PubMed ID: 38651850
[TBL] [Abstract] [Full Text] [Related]
3. Polyphyllin I enhances tumor necrosis factor-related apoptosis-inducing ligand-induced inhibition of human osteosarcoma cell growth downregulating the Wnt/β-catenin pathway.
Junli C; Fulai Z; Xingyuan S; Xiaoping MA; Peng Z; Chujie Z; Binhao S; Wenchao GU; Yongjun W; Yanping Y
J Tradit Chin Med; 2024 Apr; 44(2):251-259. PubMed ID: 38504531
[TBL] [Abstract] [Full Text] [Related]
4. Long-term outcomes with HLX01 (HanliKang
Qin Y; Song Y; Wang D; Bai O; Feng J; Sun X; Qiu L; Yang J; Yang Y; Wang Z; Hu J; Wang H; Su H; Jin Z; Qian W; Jin C; Zhang M; Yu D; Liu L; Chen G; Li Y; Sun T; Jin J; Bao H; Du X; Zhou H; Fu G; Shi Y
BMC Cancer; 2024 Jan; 24(1):124. PubMed ID: 38267866
[TBL] [Abstract] [Full Text] [Related]
5. Indirect treatment Comparisons of Mosunetuzumab With Third- and Later-Line treatments for Relapsed/Refractory Follicular Lymphoma.
Bosch F; Kuruvilla J; Vassilakopoulos TP; Maio DD; Wei MC; Zumofen MB; Nastoupil LJ
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):105-121. PubMed ID: 37981564
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review.
Huang F; Ruan Y; He X; Lian H; Yang J
World J Surg Oncol; 2023 Oct; 21(1):342. PubMed ID: 37884941
[TBL] [Abstract] [Full Text] [Related]
8. Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Hill BT; Ma S; Zent CS; Baran AM; Wallace DS; Advani A; Winter A; Winter J; Gordan L; Karmali R; Liesveld JL; Mulford DA; Rowland C; Bui A; Sportelli P; Miskin HP; Weiss MS; Friedberg JW; Barr PM
Blood Adv; 2024 Jan; 8(2):378-387. PubMed ID: 37871300
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
Duminuco A; Nardo A; Orofino A; Giunta G; Conticello C; Del Fabro V; Chiarenza A; Parisi MS; Figuera A; Leotta S; Milone G; Cupri A; Cambria D; Di Raimondo F; Romano A; Palumbo GA
Cancer; 2024 Jan; 130(1):41-50. PubMed ID: 37658645
[TBL] [Abstract] [Full Text] [Related]
10. CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases.
Petruk N; Siddiqui A; Tadayon S; Määttä J; Mattila PK; Jukkola A; Sandholm J; Selander KS
Front Immunol; 2023; 14():1179022. PubMed ID: 37533856
[TBL] [Abstract] [Full Text] [Related]
11. Clinical and Laboratory Characteristics of IgM Primary Plasma Cell Leukemia.
Wu Y; Zhang X; Ma X; Suo X; Li R
Clin Lab; 2023 Jul; 69(7):. PubMed ID: 37436385
[TBL] [Abstract] [Full Text] [Related]
12. Retrospective characterization of nodal marginal zone lymphoma.
Stuver R; Drill E; Qualls D; Okwali M; Lee Batlevi C; Caron PC; Dogan A; Epstein-Peterson ZD; Falchi L; Hamlin PA; Horwitz SM; Imber BS; Intlekofer AM; Johnson WT; Khan N; Kumar A; Lahoud OB; Lue JK; Matasar MJ; Moskowitz AJ; Noy A; Owens CN; Palomba ML; Schöder H; Vardhana SA; Yahalom J; Zelenetz AD; Salles G; Straus DJ
Blood Adv; 2023 Sep; 7(17):4838-4847. PubMed ID: 37307213
[TBL] [Abstract] [Full Text] [Related]
13. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.
Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M
Sci Transl Med; 2023 May; 15(696):eabm1262. PubMed ID: 37196067
[TBL] [Abstract] [Full Text] [Related]
14. Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortality.
Aumann S; Tsubary U; Nachmias B; Ben Yehuda D; Lavie D; Goldschmidt N; Vainstein V; Libster D; Saban R; Shaulov A; Israel S; Avni B; Grisariu S; Bdolah-Amram T; Gatt M; Zimran E
Eur J Haematol; 2023 Jul; 111(1):135-145. PubMed ID: 37096337
[TBL] [Abstract] [Full Text] [Related]
15. [Blastic plasmacytoid dendritic cell neoplasm: A clinico-pathological retrospective analysis of thirteen cases].
Nong L; Wang W; Liang L; Li D; Li X; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):308-314. PubMed ID: 37042142
[TBL] [Abstract] [Full Text] [Related]
16. Cure of Disseminated Human Lymphoma with [
Longtine MS; Shim K; Hoegger MJ; Benabdallah N; Abou DS; Thorek DLJ; Wahl RL
J Nucl Med; 2023 Jun; 64(6):924-931. PubMed ID: 37024304
[TBL] [Abstract] [Full Text] [Related]
17. Random Skin Biopsy for Diagnosis of Intravascular Large B-Cell Lymphoma: A Case Report and Literature Review.
Lv Y; Xu L; Liu X; Wang Y
Am J Dermatopathol; 2023 May; 45(5):320-322. PubMed ID: 36939136
[TBL] [Abstract] [Full Text] [Related]
18. Central nervous system involvement at initial diagnosis of extranodal NK/T-cell lymphoma: a retrospective study of a consecutive 12-year case series.
Wu W; Ren K; Li N; Luo Q; Zhou H; Hai T; Zou L
Ann Hematol; 2023 Apr; 102(4):829-839. PubMed ID: 36729147
[TBL] [Abstract] [Full Text] [Related]
19. Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.
Wallace DS; Zent CS; Baran AM; Reagan PM; Casulo C; Rice G; Friedberg JW; Barr PM
Blood Adv; 2023 Jun; 7(11):2496-2503. PubMed ID: 36689726
[TBL] [Abstract] [Full Text] [Related]
20. Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Lasater EA; Amin DN; Bannerji R; Mali RS; Barrett K; Rys RN; Oeh J; Lin E; Sterne-Weiler T; Ingalla ER; Go M; Yu SF; Krem MM; Arthur C; Hahn U; Johnston A; Karur V; Khan N; Marlton P; Phillips T; Gritti G; Seymour JF; Tani M; Yuen S; Martin S; Chang MT; Rose CM; Pham VC; Polson AG; Chang Y; Wever C; Johnson NA; Jiang Y; Hirata J; Sampath D; Musick L; Flowers CR; Wertz IE
Am J Hematol; 2023 Mar; 98(3):449-463. PubMed ID: 36594167
[TBL] [Abstract] [Full Text] [Related]
[Next]
